Chinese Journal of Antituberculosis ›› 2026, Vol. 48 ›› Issue (8): 1083-1095.doi: 10.19982/j.issn.1000-6621.20260202
• Guideline·Standard·Consensus • Next Articles
Standardization Professional Branch of Chinese Antituberculosis Association, Tuberculosis Infect Control Branch of Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis
Received:2026-04-13
Online:2026-08-01
Published:2026-07-30
Contact:
Gao Lei: Email: CLC Number:
Standardization Professional Branch of Chinese Antituberculosis Association, Tuberculosis Infect Control Branch of Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis. Guidelines for the application of tuberculin skin test[J]. Chinese Journal of Antituberculosis, 2026, 48(8): 1083-1095. doi: 10.19982/j.issn.1000-6621.20260202
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.zgflzz.cn/EN/10.19982/j.issn.1000-6621.20260202
| 目标人群 | 应用场景 | 结果解读与临床意义 |
|---|---|---|
| 结核病疑似患者 | 结核病的辅助诊断 | 结核菌素皮肤试验阳性结果为活动性结核病尤其是病原学阴性结核病的诊断和鉴别诊断提供感染证据支撑 |
| 结核分枝杆菌潜伏感染高危人群(人类免疫缺陷病毒感染者、活动性肺结核患者的密切接触者、免疫抑制剂使用者等) | 结核分枝杆菌潜伏感染诊断 | 在排除活动性结核病的前提下,结核菌素皮肤试验结果阳性提示检测对象处于结核分枝杆菌潜伏感染状态,可指导预防性治疗 |
| 结核病重点人群(学生、老年人、糖尿病患者等) | 结核病和结核分枝杆菌潜伏感染者的主动发现 | 结核菌素皮肤试验可以与其他初筛工具并联或者串联使用,提高筛查覆盖率,在发现感染者的同时,为疑似患者的发现和转诊起到分流作用。同时,结核菌素皮肤试验的检测结果还可支撑重点人群中预防性治疗对象的主动发现 |
| [1] | 成诗明, 王国治, 王黎霞, 等. 结核菌素皮肤试验使用指导手册[S]. 北京: 人民卫生出版社, 2014. |
| [2] | 中国疾病预防控制中心. 中国结核病防治工作技术指南[M]. 北京: 中国疾病预防控制中心, 2021. |
| [3] | World Health Organization. WHO Consolidated Guidelines on Tuberculosis. Module 3:Diagnosis. Tests for tuberculosis Infection[R]. Geneva: World Health Organization, 2022. |
| [4] | 中华医学会呼吸病学分会, 国家呼吸医学中心. 中国结核病预防性治疗指南[M]. 北京: 人民卫生出版社, 2023. |
| [5] | 中国防痨协会结核病控制专业分会, 中国防痨协会标准化专业分会, 中国防痨协会老年结核病防治专业分会. 结核分枝杆菌感染检测技术应用专家共识[J]. 中国防痨杂志, 2025, 47(7): 813-829. doi:10.19982/j.issn.1000-6621.20250231. |
| [6] | Zhou G, Luo Q, Luo S, et al. Positive rates of interferon-γ release assay and tuberculin skin test in detection of latent tuberculosis infection: A systematic review and meta-analysis of 200,000 head-to-head comparative tests[J]. Clin Immunol, 2022, 245: 109132. doi:10.1016/j.clim.2022.109132. |
| [7] | Gao L, Lu W, Bai L, et al. Latent tuberculosis infection in rural China: baseline results of a population-based, multicentre, prospective cohort study[J]. Lancet Infect Dis, 2015, 15(3): 310-319. doi:10.1016/S1473-3099(14)71085-0. |
| [8] |
Yu X, Liu P, Liu G, et al. The prevalence of non-tuberculous mycobacterial infections in mainland China: Systematic review and meta-analysis[J]. J Infect, 2016, 73(6): 558-567. doi:10.1016/j.jinf.2016.08.020.
pmid: 27717784 |
| [9] | World Health Organization. WHO consolidated guidelines on tuberculosis. Module 1: prevention-tuberculosis preventive treatment, second edition[R]. Geneva: World Health Organization, 2024. |
| [10] | Wang W, Liu A, Liu X, et al. Mycobacterium tuberculosis Infection in School Contacts of Tuberculosis Cases: A Systematic Review and Meta-Analysis[J]. Am J Trop Med Hyg, 2024, 110(6): 1253-1260. doi:10.4269/ajtmh.23-0038. |
| [11] |
Sun L, Qi X, Guo Y, et al. Tuberculosis infection screening in children with close contact: a hospital-based study[J]. BMC Infect Dis, 2021, 21(1): 815. doi:10.1186/s12879-021-06480-2.
pmid: 34388985 |
| [12] | Campbell JR, Winters N, Menzies D. Absolute risk of tuberculosis among untreated populations with a positive tuberculin skin test or interferon-gamma release assay result: systematic review and meta-analysis[J]. BMJ, 2020, 368: m549. doi:10.1136/bmj.m549. |
| [13] |
Anibarro L, Trigo M, Villaverde C, et al. Interferon-γ release assays in tuberculosis contacts: is there a window period?[J]. Eur Respir J, 2011, 37(1): 215-217. doi:10.1183/09031936.00030610.
pmid: 21205718 |
| [14] | Menzies D. Interpretation of repeated tuberculin tests. Boosting, conversion, and reversion[J]. Am J Respir Crit Care Med, 1999, 159(1): 15-21. doi:10.1164/ajrccm.159.1.9801120. |
| [15] |
Jones-López E C, Acuña-Villaorduña C, Fregona G, et al. Incident Mycobacterium tuberculosis infection in household contacts of infectious tuberculosis patients in Brazil[J]. BMC Infect Dis, 2017, 17(1): 576. doi:10.1186/s12879-017-2675-3.
pmid: 28821234 |
| [16] | Ribeiro-Rodrigues R, Kim S, Coelho da Silva F D, et al. Discordance of tuberculin skin test and interferon gamma release assay in recently exposed household contacts of pulmonary TB cases in Brazil[J]. PLoS One, 2014, 9(5): e96564. doi:10.1371/journal.pone.0096564. |
| [17] |
Hill P C, Jeffries D J, Brookes R H, et al. Using ELISPOT to expose false positive skin test conversion in tuberculosis contacts[J]. PLoS One, 2007, 2(1): e183. doi:10.1371/journal.pone.0000183.
pmid: 17264885 |
| [18] | 周建伟, 张松桃, 李占辉, 等. 学校肺结核疫情密切接触者基线筛查及随访队列研究[J]. 结核与肺部疾病杂志, 2023, 4(2): 120-127. doi:10.19983/j.issn.2096-8493.20220164. |
| [19] | Hamada Y, Gupta R K, Quartagno M, et al. Predictive performance of interferon-gamma release assays and the tuberculin skin test for incident tuberculosis: an individual participant data meta-analysis[J]. EClinicalMedicine, 2023, 56: 101815. doi:10.1016/j.eclinm.2022.101815. |
| [20] | Xin H, Du J, Cao X, et al. Association of tuberculosis infection with the development of active tuberculosis and comorbidities in rural China: a 10-year follow-up results of a population-based, multicentre, prospective study[J]. Lancet Reg Health West Pac, 2025, 61: 101659. doi:10.1016/j.lanwpc.2025.101659. |
| [21] | Zhou G, Luo Q, Luo S, et al. Interferon-γ release assays or tuberculin skin test for detection and management of latent tuberculosis infection: a systematic review and meta-analysis[J]. Lancet Infect Dis, 2020, 20(12): 1457-1469. doi:10.1016/S1473-3099(20)30276-0. |
| [22] | Akolo C, Adetifa I, Shepperd S, et al. Treatment of latent tuberculosis infection in HIV infected persons[J]. Cochrane Database Syst Rev, 2010, 2010(1): CD000171. doi:10.1002/14651858.CD000171.pub3. |
| [23] | Ayele H T, van Mourik M S M, Debray T P A, et al. Isoniazid Prophylactic Therapy for the Prevention of Tuberculosis in HIV Infected Adults: A Systematic Review and Meta-Analysis of Randomized Trials[J]. PLoS One, 2015, 10(11): e0142290. doi:10.1371/journal.pone.0142290. |
| [24] |
Chaisson L H, Saraceni V, Cohn S. CD4+ cell count stratification to guide tuberculosis preventive therapy for people living with HIV[J]. AIDS, 2020, 34(1): 139-147. doi:10.1097/QAD.0000000000002398.
pmid: 31634189 |
| [25] | Rangaka M X, Wilkinson R J, Boulle A, et al. Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial[J]. Lancet, 2014, 384(9944): 682-690. doi:10.1016/S0140-6736(14)60162-8. |
| [26] |
Ross J M, Badje A, Rangaka M X, et al. Isoniazid preventive therapy plus antiretroviral therapy for the prevention of tuberculosis: a systematic review and meta-analysis of individual participant data[J]. Lancet HIV, 2021, 8(1):e8-e15. doi:10.1016/S2352-3018(20)30299-X.
pmid: 33387480 |
| [27] |
Mandalakas A M, Hesseling A C, Gie R P, et al. Modelling the cost-effectiveness of strategies to prevent tuberculosis in child contacts in a high-burden setting[J]. Thorax, 2013, 68(3): 247-255. doi:10.1136/thoraxjnl-2011-200933.
pmid: 22717944 |
| [28] | Balfour A, Masina N, Queiroz A T L, et al. Two distinct cytokine response clusters identified in healthcare workers with apparent resistance to infection with Mycobacterium tuberculosis despite sustained occupational exposure[J]. bioRxiv, 2025, 2025.03.27.643001. doi:10.1101/2025.03.27.643001. |
| [29] | Wang B, Chen S, Liu X, et al. Effectiveness of tuberculosis preventive treatment in patients with rheumatic diseases: a global systematic review and meta-analysis[J]. EClinicalMedicine, 2025, 82: 103177. doi:10.1016/j.eclinm.2025.103177. |
| [30] | Collins J M, Hunter M, Gordon W, et al. False-Positive Tuberculin Skin Test Results Among Low-Risk Healthcare Workers Following Implementation of Fifty-Dose Vials of Purified Protein Derivative[J]. Infect Control Hosp Epidemiol, 2018, 39(6): 750-752. doi:10.1017/ice.2018.59. |
| [31] | Horwitz O, Bunch-Christensen K. Correlation between tuberculin sensitivity after 2 months and 5 years among BCG vaccinated subjects[J]. Bull World Health Organ, 1972, 47(1): 49-58. |
| [32] |
Ashley M J, Siebenmann C O. Tuberculin skin sensitivity following BCG vaccination with vaccines of high and low viable counts[J]. Can Med Assoc J, 1967, 97(22): 1335-1339.
pmid: 6061598 |
| [33] |
Marcus J H, Khassis Y. The tuberculin sensitivity in BCG vaccinated infants and children in Israel[J]. Acta Tuberc Pneumol Scand, 1965, 46(2): 113-122.
pmid: 5879241 |
| [34] |
Joncas J H, Robitaille R, Gauthier T. Interpretation of the PPD skin test in BCG-vaccinated children[J]. Can Med Assoc J, 1975, 113(2): 127-128.
pmid: 1139496 |
| [35] |
Magnus K, Edwards L B. The effect of repeated tuberculin testing on post-vaccination allergy; a preliminary note[J]. Lancet, 1955, 269(6891): 643-644.
pmid: 13252947 |
| [36] |
Wang L, Turner M O, Elwood R K. A meta-analysis of the effect of Bacille Calmette Guérin vaccination on tuberculin skin test measurements[J]. Thorax, 2002, 57(9): 804-809. doi:10.1136/thorax.57.9.804.
pmid: 12200526 |
| [37] |
Farhat M, Greenaway C, Pai M, et al. False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria?[J]. Int J Tuberc Lung Dis, 2006, 10(11): 1192-1204.
pmid: 17131776 |
| [38] | Li H, Xin H, Qian S, et al. Testing of tuberculosis infection among Chinese adolescents born after terminating the Bacillus Calmette-Guérin booster vaccination: subgroup analysis of a population-based cross-sectional study[J]. Front Med, 2017, 11(4): 528-535. doi:10.1007/s11684-017-0573-0. |
| [39] | Cao X, Gao L, Xin H, et al. The dynamic change of tuberculosis infection prevalence in rural residents: 10-year follow-up of a population-based, multicentre cohort study from China[J]. Lancet Reg Health West Pac, 2025, 56: 101509. doi:10.1016/j.lanwpc.2025.101509. |
| [40] | Gao L, Jin Q. Differences in BCG vaccination and tuberculin skin-test positivity-Authors’ reply[J]. Lancet Infect Dis, 2015, 15(9): 1003-1005. doi:10.1016/S1473-3099(15)00251-0. |
| [41] | 高磊, 权竹声, 成君. 结核分枝杆菌感染检测两步法在学校结核病控制工作中的应用探讨[J]. 中华预防医学杂志, 2020, 54(4): 385-391. doi:10.3760/cma.j.cn112150-20191204-00909. |
| [42] | 中国防痨协会. T/CHATA 016-2021 结核菌素皮肤试验-γ 干扰素释放试验两步法的操作技术规范[M]. 北京: 中国防痨协会, 2021. |
| [43] |
Erkens C G M, Dinmohamed A G, Kamphorst M, et al. Added value of interferon-gamma release assays in screening for tuberculous infection in the Netherlands[J]. Int J Tuberc Lung Dis, 2014, 18(4): 413-420. doi:10.5588/ijtld.13.0589.
pmid: 24670695 |
| [44] |
Diel R, Nienhaus A, Loddenkemper R. Cost-effectiveness of interferon-gamma release assay screening for latent tuberculosis infection treatment in Germany[J]. Chest, 2007, 131(5): 1424-1434. doi:10.1378/chest.06-2728.
pmid: 17494792 |
| [45] |
Pooran A, Booth H, Miller R F, et al. Different screening strategies (single or dual) for the diagnosis of suspected latent tuberculosis: a cost effectiveness analysis[J]. BMC Pulm Med, 2010, 10: 7. doi:10.1186/1471-2466-10-7.
pmid: 20170555 |
| [46] |
Nienhaus A, Schablon A, Costa J T, et al. Systematic review of cost and cost-effectiveness of different TB-screening strategies[J]. BMC Health Serv Res, 2011, 11: 247. doi:10.1186/1472-6963-11-247.
pmid: 21961888 |
| [47] | Internal Clinical Guidelines Team (UK). Tuberculosis: Prevention, Diagnosis, Management and Service Organisation[R]. London: National Institute for Health and Care Excellence, 2016. |
| [48] | de Santé H A. Tests in vitro de dépistage de l’infection tuberculeuse latente par détection de production d’interféron gamma[R]. Saint-Denis La Plaine: Haute Autorité de Santé, 2015. |
| [49] |
Schaberg T, Bauer T, Brinkmann F, et al. Tuberculosis Guideline for Adults-Guideline for Diagnosis and Treatment of Tuberculosis including LTBI Testing and Treatment of the German Central Committee (DZK) and the German Respiratory Society (DGP)[J]. Pneumologie, 2017, 71(6): 325-397. doi:10.1055/s-0043-105954.
pmid: 28651293 |
| [50] |
Muñoz L, Santin M. Interferon-γ release assays versus tuberculin skin test for targeting people for tuberculosis preventive treatment: an evidence-based review[J]. J Infect, 2013, 66(4): 381-387. doi:10.1016/j.jinf.2012.12.005.
pmid: 23298892 |
| [51] |
Muñoz L, Santin M, Alcaide F, et al. QuantiFERON-TB Gold In-Tube as a Confirmatory Test for Tuberculin Skin Test in Tuberculosis Contact Tracing: A Noninferiority Clinical Trial[J]. Clin Infect Dis, 2018, 66(3): 396-403. doi:10.1093/cid/cix745.
pmid: 29020191 |
| [52] |
Kim H J, Lee G H, Ryoo S, et al. Role of confirmatory interferon-gamma release assays in school outbreaks of tuberculosis in South Korea[J]. Int J Tuberc Lung Dis, 2015, 19(5): 576-581. doi:10.5588/ijtld.14.0636.
pmid: 25868027 |
| [53] |
Song S, Jeon D, Kim J W, et al. Performance of confirmatory interferon-γ release assays in school TB outbreaks[J]. Chest, 2012, 141(4): 983-988. doi:10.1378/chest.11-1158.
pmid: 21980060 |
| [54] | van Zyl-Smit R N, Zwerling A, Dheda K, et al. Within-subject variability of interferon-g assay results for tuberculosis and boosting effect of tuberculin skin testing: a systematic review[J]. PLoS One, 2009, 4(12): e8517. doi:10.1371/journal.pone.0008517. |
| [55] |
Menzies R, Vissandjee B, Rocher I, et al. The booster effect in two-step tuberculin testing among young adults in Montreal[J]. Ann Intern Med, 1994, 120(3): 190-198. doi:10.7326/0003-4819-120-3-199402010-00003.
pmid: 8273982 |
| [56] |
Teixeira E G, Kritski A, Ruffino-Netto A, et al. Two-step tuberculin skin test and booster phenomenon prevalence among Brazilian medical students[J]. Int J Tuberc Lung Dis, 2008, 12(12): 1407-1413.
pmid: 19017450 |
| [57] |
Salles C G, Ruffino-Netto A, Lapa-e-Silva J R. The presence of a booster phenomenon among contacts of active pulmonary tuberculosis cases: a retrospective cohort[J]. BMC Public Health, 2007, 7: 38. doi:10.1186/1471-2458-7-38.
pmid: 17371600 |
| [58] | Gordin F M, Perez-Stable E J, Flaherty D, et al. Evaluation of a third sequential tuberculin skin test in a chronic care population[J]. Am Rev Res Dis, 1988, 137(1): 153-157. doi:10.1164/ajrccm/137.1.153. |
| [59] | 葛广秀, 彭义利, 邱美玲, 等. 结核菌素试验复强反应发生率及机理的探讨[J]. 中国防痨杂志, 1995, 17(4): 173-175. |
| [60] | Elamin S, Ibrahim S S, Ad El-Mahdi H, et al. Screening hemodialysis patients for tuberculosis in Sudan[J]. Ind J Tuberc, 2025, 72(3): 358-361. doi:10.1016/j.ijtb.2024.08.013. |
| [61] | Riestra S, Taxonera C, Zabana Y, et al. Performance of Screening Strategies for Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease: Results from the ENEIDA Registry of GETECCU[J]. J Clin Med, 2022, 11(13): 2685. doi:10.3390/jcm11133915. |
| [62] | Akcay A, Erdem Y, Altun B, et al. The booster phenomenon in 2-step tuberculin skin testing of patients receiving long-term hemodialysis[J]. Am J Infect Control, 2003, 31(6): 371-374. doi:10.1016/s0196-6553(02)48238-7. |
| [63] |
Jensen P A, Lambert L A, Iademarco M F, et al. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005[J]. MMWR Recomm Rep, 2005, 54(RR-17): 1-141.
pmid: 16382216 |
| [64] | 中华医学会感染病学分会艾滋病学组, 中国疾病预防控制中心. 中国艾滋病诊疗指南 (2024版)[J]. 中华临床感染病杂志, 2024, 17(3): 161-190. doi:10.13419/j.cnki.aids.2024.08.01. |
| [1] | Liu Zisen, Zhao Yaqi, Zhang Bin, Xin Henan, Du Jiang, Feng Boxuan, He Yijun, Li Zihan, Yu Yilin, Wang Dakuan, Yan Jiaoxia, Gao Lei, Jin Qi, Duan Weitao, Cao Xuefang. Analysis of re-screening for latent tuberculosis infection in 2025 and related factors affecting infection status among rural doctors in Zhongmu County, Henan Province, based on 2017 screening [J]. Chinese Journal of Antituberculosis, 2026, 48(8): 1139-1147. |
| [2] | Zeng Lina, Li Wensi, Lu Hailin, Wang Wenfei, Chen Xinchun, Deng Guofang, Xie Shuixiang. Advances in Mycobacterium tuberculosis regulation of host lipid metabolism reprogramming [J]. Chinese Journal of Antituberculosis, 2026, 48(8): 1214-1219. |
| [3] | Xia Hongli, Hua Jiao, Lu Jiankang. Investigation results and analysis of associated factors of tuberculosis infection and disease among school students in Xichang City, Sichuan Province, 2023 [J]. Chinese Journal of Antituberculosis, 2026, 48(8): 1130-1138. |
| [4] | Wang Congli, Wang Haoran, Huang Hairong, Jiang Guanglu. Performance evaluation of the Genewise-MTBC System in the rapid detection of the Mycobacterium tuberculosis complex [J]. Chinese Journal of Antituberculosis, 2026, 48(7): 985-991. |
| [5] | Chinese Antituberculosis Association, Nutrition Branch of the Chinese Antituberculosis Association, Hunan Antituberculosis Association, Hunan Institute for Tuberculosis Control (Hunan Chest Hospital), Shanghai Pulmonary Hospital, Xiangya School of Public Health, Central South University. Expert consensus on nutritional therapy for tuberculosis and diabetes mellitus comorbidity [J]. Chinese Journal of Antituberculosis, 2026, 48(7): 913-924. |
| [6] | Qiao Xiaobo, Li Jing, Wang Baoqian, Zhou Weidong, Wang Fei, Zhang Qibo, Li Tongxia. Study on the diagnostic value of GeneXpert MTB/RIF and BACTEC MGIT 960 in bronchoalveolar lavage fluid combined with peripheral blood IGRA testing for etiologically negative pulmonary tuberculosis diagnosis [J]. Chinese Journal of Antituberculosis, 2026, 48(6): 874-881. |
| [7] | Li Jing, Chen Shuangshuang, Chen Chunhua, Yang Guoxiang, Yang Chengnao, Zheng Luyun, Tan Chengjian, Li Chuanyou, Li Jie, Zhou Peifu, Dai Xiaowei. Screening of anti-tuberculosis activity and analysis of chemical constituents of the Ethnomedicine Botrychium ternatum [J]. Chinese Journal of Antituberculosis, 2026, 48(6): 787-794. |
| [8] | Jiang Xuefeng, Zhou Linjun, Sun Yan, Jiang Mingxia, Ma Ling, Mei Li, Liu Dongxin. Analysis of drug resistance gene mutation characteristics in Mycobacterium tuberculosis strains from five northwestern provinces of China [J]. Chinese Journal of Antituberculosis, 2026, 48(6): 856-864. |
| [9] | Wu Yaning, Huang Misun, Guo Yi, Bo Xianglong, Wang Ruihuan, Xing Jianliang, Fan Xueting, Xu Da, Zhao Lili, Zhao Xiuqin, Li Guilian, Liu Haican, Li Machao. Analysis of genetic mutation characteristics associated with linezolid resistance in Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2026, 48(5): 603-615. |
| [10] | Hu Xinyang, Liu Yang, Gao Jingtao. Research progress on latent tuberculosis infection in patients with hematological malignancies [J]. Chinese Journal of Antituberculosis, 2026, 48(5): 694-699. |
| [11] | Che Yang, Zhang Dongliang, Li Xiangchen, Lu Yewei, Liu Zhengwei. Molecular characterization and risk factors of cross-resistance between isoniazid and prothionamide in multidrug-resistant Mycobacterium tuberculosis in Ningbo, China [J]. Chinese Journal of Antituberculosis, 2026, 48(5): 576-585. |
| [12] | Huang Zhenyang, Li Wenjun, Sun Yansong, Li Hao. Advances in CRISPR-Cas system-based detection of Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2026, 48(5): 707-715. |
| [13] | Miao Honghao, Zhang Jie, Pang Mengdi, Ren Yixuan, Deng Yang, Yi Junli, Fan Ruifang, Chen Shuangshuang, Chen Hao, Yu Lan, Li Jie, Li Chuanyou, Yang Xinyu. Genotypic and drug resistance of Mycobacterium tuberculosis in Beijing,2024 [J]. Chinese Journal of Antituberculosis, 2026, 48(4): 477-484. |
| [14] | Li Jing, Zhang Yangyi, Yang Jinghui, Wu Zheyuan, Li Ningdi, Yu Chenlei, Wang Lili, Shen Xuhui, Jiang Yuan, Shen Xin. Study on the characteristics of rpoB gene mutations in Mycobacterium tuberculosis and its correlation with rifampicin resistance level in Shanghai [J]. Chinese Journal of Antituberculosis, 2026, 48(4): 485-494. |
| [15] | Jiang Lina, Dai Wenxi, Ju Hanfang, Meng Sukai, Wang Chunhua. Clinical value of auramine O fluorescence staining automatic microscopic scanning and recognition system for detecting tuberculosis [J]. Chinese Journal of Antituberculosis, 2026, 48(4): 504-509. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
京公网安备11010202007215号
Total visitors: Visitors of today: Now online:
This work is licensed under Creative Commons Attribution 3.0 License.